Navigation Links
ERT to Announce 2009 Third Quarter Results on October 29, 2009
Date:10/21/2009

PHILADELPHIA, Oct. 21 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized ECG, ePRO, eClinical technology, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will release its results for the 2009 third quarter on Thursday, October 29, 2009 after the market closes. After the release, the Company will host a conference call at 5:00 PM EDT that day.

For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.

This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=63252. The webcast can be accessed for up to one year on either site.

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the biopharmaceutical, medical device, and related industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including but not limited to 2009 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope, and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE ERT


'/>"/>
SOURCE ERT
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
2. Winners Announced in 2009 Collegiate Inventors Competition(R)
3. BioWa and NKTT Announce Licensing of BioWas POTELLIGENT(R) Technology For Use in Antibody Research and Development
4. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
5. Professional Pricing Society Announces Educational Partnership with Vendavo -- "PPS Accepting Vendavo Pricing Knowledge Series Awards to Certified Pricing Professional Program"
6. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
7. Vasogen Inc. and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger
8. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
9. China Medical Technologies Announces the SFDA Approval for its SPR System
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... VIRGINIA (PRWEB) , ... May 17, 2017 , ... NDA ... business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development ... addition to his position at Eurofins and Cardinal Health, he was former Chief Operating ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, is ... UDIs and Traceability for Medical Devices conference in Brussels, Belgium. , Crowley played ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated neurological disorders ... develop Alzheimer’s disease, while men are at greater risk for Parkinson’s disease. Understanding ... is the aim of a research program at Worcester Polytechnic Institute (WPI) funded ...
Breaking Biology Technology:
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):